Background: Glucagon-like peptide 1 receptor agonists (GLP-1RA) are currently not approved for use in people with T1D (PwT1D). At present there is limited safety and efficacy data using these agents in PwT1D. We analyzed the association of GLP-1RA on HbA1c levels and weight in PwT1D.

Methods: Electronic medical record data from T1D Exchange Quality Improvement Collaborative, including 13 endocrinology clinics across the United States was subcategorized by age, race/ethnicity, gender, insurance type use as well as type of GLP-1RA prescribed. Analysis included PwT1D, 20 years of age or older with at least two prescriptions of the same GLP-1RA. BMI and HbA1c prior to GLP-1RA use and 6-12 months after the initiation of GLP-1RA were analyzed using t and chi square tests as appropriate (Table 1).

Results: The population consisted of 481 PwT1D using GLP1RA. Of these individuals, 53% were non-Hispanic White, 70% were female, and 90% were prescribed long acting GLP-1RA. There was a reduction in the mean HbA1c level from 7.5 to 7.3 (p=0.04). No significant differences were found in BMI or DKA events.

Conclusions: HbA1c levels decreased after 6-12 months on a GLP-1RA. Prospective research should further clarify use, optimal dosing, and potential benefits, including cardiovascular risk reduction, of GLP1-RA medication for PwT1D.

graphic
View largeDownload slide
Disclosure

C.J. Levy: Research Support; Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; MannKind Corporation, T1D Exchange, Tandem Diabetes Care, Inc., Abbott, Insulet Corporation. M. Gillis: None. M. Gallagher: None. M. Basina: None. V.N. Shah: Consultant; Dexcom, Inc., Insulet Corporation. Research Support; Insulet Corporation. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Sanofi, Medscape. Consultant; embecta, Tandem Diabetes Care, Inc. E.L. Ospelt: None. S. Rompicherla: None. E. Breidbart: None. M. Zupa: None. O. Ebekozien: Advisory Panel; Sanofi, Medtronic. Research Support; Vertex Pharmaceuticals Incorporated. Speaker's Bureau; Vertex Pharmaceuticals Incorporated. Research Support; Medtronic, Lilly Diabetes, Abbott, Dexcom, Inc.

Funding

The Leona M. and Harry B. Helmsley Charitable Trust

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.